Showing results (91-100 of 166) with videos related to

Sort By:
Pageof 17
Cancer Reports (Hoboken, N.J.)|June 11, 2021
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experienceAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 29, 2026
Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and TremelimumabKazuhiro Nouso, Akiko Wakuta, Shohei Shiota, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 1, 2026
Long-Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort StudySatoru Kakizaki, Tadashi Ikegami, Takeshi Hatanaka, et al.
European Journal of Gastroenterology & Hepatology|July 8, 2022
Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
JCO Clinical Cancer Informatics|May 12, 2025
Prognostic Significance of the BALAD Serological Model in Systemic Therapies for Hepatocellular Carcinoma: A Personalized Approach to the Prediction of Survival BenefitHidenori Toyoda, Atsushi Hiraoka, Hironori Ochi, et al.
Scientific Reports|May 19, 2022
C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinibToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Cancer Medicine|December 9, 2022
New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation studyToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Cancer Medicine|September 26, 2022
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysisTakeshi Hatanaka, Atsushi Naganuma, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 26, 2022
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysisTakeshi Hatanaka, Atsushi Hiraoka, Toshifumi Tada, et al.
European Journal of Gastroenterology & Hepatology|February 16, 2022
Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Pageof 17